TR201902690T4 - ROS KINASE IN LUNG CANCER. - Google Patents
ROS KINASE IN LUNG CANCER. Download PDFInfo
- Publication number
- TR201902690T4 TR201902690T4 TR2019/02690T TR201902690T TR201902690T4 TR 201902690 T4 TR201902690 T4 TR 201902690T4 TR 2019/02690 T TR2019/02690 T TR 2019/02690T TR 201902690 T TR201902690 T TR 201902690T TR 201902690 T4 TR201902690 T4 TR 201902690T4
- Authority
- TR
- Turkey
- Prior art keywords
- assay
- ros
- polypeptide
- seo
- lung cancer
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Pulmonology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/113,676 US20120208824A1 (en) | 2006-01-20 | 2011-05-23 | ROS Kinase in Lung Cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR201902690T4 true TR201902690T4 (en) | 2019-04-22 |
Family
ID=46208827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2019/02690T TR201902690T4 (en) | 2011-05-23 | 2012-05-23 | ROS KINASE IN LUNG CANCER. |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20120208824A1 (https=) |
| EP (3) | EP3492918B1 (https=) |
| JP (3) | JP6210977B2 (https=) |
| KR (1) | KR102123963B1 (https=) |
| CN (2) | CN106148525B (https=) |
| CA (2) | CA3020650C (https=) |
| DK (2) | DK2715365T3 (https=) |
| ES (2) | ES2716980T3 (https=) |
| HU (1) | HUE041780T2 (https=) |
| PT (1) | PT3182128T (https=) |
| SI (1) | SI3182128T1 (https=) |
| TR (1) | TR201902690T4 (https=) |
| WO (1) | WO2012162373A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120208824A1 (en) | 2006-01-20 | 2012-08-16 | Cell Signaling Technology, Inc. | ROS Kinase in Lung Cancer |
| EP3266795A1 (en) | 2009-02-12 | 2018-01-10 | Cell Signaling Technology, Inc. | Method for detecting a fig-ros fusion polynucleotide |
| EP3470513B1 (en) * | 2013-03-15 | 2020-05-13 | Expression Pathology, Inc. | Srm assay to indicate cancer therapy |
| EP3092495B1 (en) * | 2014-01-06 | 2020-11-25 | Expression Pathology, Inc. | Srm assay for pd-l1 |
| WO2017153932A1 (en) | 2016-03-10 | 2017-09-14 | Novartis Ag | Strn-alk fusion as a therapeutic target in gastric cancer |
| WO2017175111A1 (en) | 2016-04-04 | 2017-10-12 | Novartis Ag | Strn-alk fusion as a therapeutic target in colorectal cancer |
| EP3592338A1 (en) * | 2017-03-08 | 2020-01-15 | ARIAD Pharmaceuticals, Inc. | Pharmaceutical formulations comprising 5-chloro-n4 |
| KR101987065B1 (ko) | 2017-08-07 | 2019-06-10 | 주식회사 싸이토젠 | Eml4-alk유전자 변이 분석방법 |
| KR102167739B1 (ko) | 2018-10-31 | 2020-10-19 | 한국과학기술연구원 | Alk 또는 ros-1 인산화 효소 억제제 스크리닝을 위한 방법, 조성물 및 키트 및 방법 |
| JP7313033B2 (ja) * | 2019-03-01 | 2023-07-24 | 国立大学法人北海道大学 | Ｉｋｚｆ１遺伝子変異を検出するための核酸プローブセット及び当該プローブセットを用いたｉｋｚｆ１遺伝子変異の検出方法 |
| CN110632318B (zh) * | 2019-10-28 | 2023-04-07 | 四川大学华西医院 | Tpm3自身抗体检测试剂在制备肺癌筛查试剂盒中的用途 |
| CN111440241B (zh) * | 2020-05-31 | 2021-01-05 | 广东赛尔生物科技有限公司 | 一种包含特异性结合ros1的单克隆抗体的癌症检测试剂盒 |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3023787A1 (de) | 1980-06-25 | 1982-01-21 | Studiengesellschaft Kohle mbH, 4330 Mülheim | Verfahren zur erhoehung der inkorporation und der expression von genetischem material in die kerne von intakten zellen mit hilfe von liposomen |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4659678A (en) | 1982-09-29 | 1987-04-21 | Serono Diagnostics Limited | Immunoassay of antigens |
| NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4727022A (en) | 1984-03-14 | 1988-02-23 | Syntex (U.S.A.) Inc. | Methods for modulating ligand-receptor interactions and their application |
| DE3586772T2 (de) | 1984-07-24 | 1993-03-04 | Coselco Mimotopes Pty Ltd | Verfahren zur bestimmung von mimotopen. |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5756696A (en) | 1986-01-16 | 1998-05-26 | Regents Of The University Of California | Compositions for chromosome-specific staining |
| US5447841A (en) | 1986-01-16 | 1995-09-05 | The Regents Of The Univ. Of California | Methods for chromosome-specific staining |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US6121424A (en) | 1991-11-25 | 2000-09-19 | Enzon, Inc. | Multivalent antigen-binding proteins |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP0394827A1 (en) | 1989-04-26 | 1990-10-31 | F. Hoffmann-La Roche Ag | Chimaeric CD4-immunoglobulin polypeptides |
| EP0452457B1 (en) | 1989-11-03 | 1997-08-20 | Vanderbilt University | Method of in vivo delivery of functioning foreign genes |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| ES2225816T5 (es) | 1990-02-01 | 2014-08-21 | Siemens Healthcare Diagnostics Products Gmbh | Producción y utilización de bancos de genes de anticuerpos humanos ("bibliotecas de anticuerpos humanos") |
| DE4002897A1 (de) | 1990-02-01 | 1991-08-08 | Behringwerke Ag | Herstellung und verwendung von genbanken synthetischer menschlicher antikoerper ("synthetische human-antikoerper-bibliotheken") |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5491224A (en) | 1990-09-20 | 1996-02-13 | Bittner; Michael L. | Direct label transaminated DNA probe compositions for chromosome identification and methods for their manufacture |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| EP0786522A2 (en) | 1992-07-17 | 1997-07-30 | Ribozyme Pharmaceuticals, Inc. | Enzymatic RNA molecules for treatment of stenotic conditions |
| US6710174B2 (en) | 2001-09-13 | 2004-03-23 | Isis Pharmaceuticals, Inc. | Antisense inhibition of vascular endothelial growth factor receptor-1 expression |
| IL108367A0 (en) | 1993-01-27 | 1994-04-12 | Hektoen Inst For Medical Resea | Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells |
| US6340674B1 (en) | 1993-03-26 | 2002-01-22 | Thomas Jefferson University | Method of inhibiting the proliferation and causing the differentiation of cells with IGF-1 receptor antisense oligonucleotides |
| US5480971A (en) | 1993-06-17 | 1996-01-02 | Houghten Pharmaceuticals, Inc. | Peralkylated oligopeptide mixtures |
| US5529925A (en) | 1993-12-03 | 1996-06-25 | St. Jude Children's Research Hospital | Nucleic acid sequences and fusion proteins present in human t(2;5) lymphoma |
| DE69534347T2 (de) | 1994-01-31 | 2006-05-24 | Trustees Of Boston University, Boston | Bibliotheken aus Polyklonalen Antikörpern |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| US5820873A (en) | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| US5753613A (en) | 1994-09-30 | 1998-05-19 | Inex Pharmaceuticals Corporation | Compositions for the introduction of polyanionic materials into cells |
| US5783683A (en) | 1995-01-10 | 1998-07-21 | Genta Inc. | Antisense oligonucleotides which reduce expression of the FGFRI gene |
| US5675063A (en) | 1995-02-28 | 1997-10-07 | Loyola University Of Chicago | Immortalized rabbit hybridoma fusion partner |
| ES2176484T3 (es) | 1995-08-18 | 2002-12-01 | Morphosys Ag | Bancos de proteinas/(poli)peptidos. |
| US6395713B1 (en) | 1997-07-23 | 2002-05-28 | Ribozyme Pharmaceuticals, Inc. | Compositions for the delivery of negatively charged molecules |
| US6617162B2 (en) | 2001-12-18 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Antisense modulation of estrogen receptor alpha expression |
| CA2315256A1 (en) | 1997-12-16 | 1999-06-24 | Valentis, Inc. | Needle-free injection of formulated nucleic acid molecules |
| US7300753B2 (en) | 1998-09-04 | 2007-11-27 | John Rush | Immunoaffinity isolation of modified peptides from complex mixtures |
| US7198896B2 (en) | 1998-09-04 | 2007-04-03 | Cell Signaling Technology, Inc. | Immunoaffinity isolation of modified peptides from complex mixtures |
| US6573043B1 (en) | 1998-10-07 | 2003-06-03 | Genentech, Inc. | Tissue analysis and kits therefor |
| DE60040274D1 (de) | 1999-03-10 | 2008-10-30 | Phogen Ltd | Verabreichung von nukleinsäuren und proteinen an zellen |
| US7662793B2 (en) | 1999-06-18 | 2010-02-16 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from a Pol III promoter |
| US7829693B2 (en) | 1999-11-24 | 2010-11-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
| ES2336887T5 (es) | 2000-03-30 | 2019-03-06 | Whitehead Inst Biomedical Res | Mediadores de interferencia por ARN específicos de secuencias de ARN |
| AU8843701A (en) | 2000-09-09 | 2002-03-22 | Univ New York State Res Found | Method and compositions for isolating metastatic cancer cells, and use in measuring metastatic potential of a cancer thereof |
| CA2429814C (en) | 2000-12-01 | 2014-02-18 | Thomas Tuschl | Rna interference mediating small rna molecules |
| ME00502B (me) | 2001-01-05 | 2011-10-10 | Amgen Fremont Inc | Antitjela za insulinu sličan receptor faktora i rasta |
| US7313482B2 (en) | 2001-05-17 | 2007-12-25 | The Public Health Research Institute Of The City Of New York, Inc. | Selection of target sites for antisense attack of RNA |
| US20030170891A1 (en) | 2001-06-06 | 2003-09-11 | Mcswiggen James A. | RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| US20040209832A1 (en) | 2001-11-30 | 2004-10-21 | Mcswiggen James | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| CA2450793A1 (en) | 2001-06-20 | 2002-12-27 | Prochon Biotech Ltd. | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| WO2003016861A2 (en) | 2001-08-14 | 2003-02-27 | President And Fellows Of Harvard College | Absolute quantification of proteins and modified forms thereof by multistage mass spectrometry |
| US20030219839A1 (en) | 2001-09-20 | 2003-11-27 | Katherine Bowdish | Anti-PDGF antibodies and methods for producing engineered antibodies |
| US6734017B2 (en) | 2001-09-28 | 2004-05-11 | Isis Pharmaceuticals, Inc. | Antisense modulation of vascular endothelial growth factor receptor-2 expression |
| DE10230997A1 (de) | 2001-10-26 | 2003-07-17 | Ribopharma Ag | Medikament zur Erhöhung der Wirksamkeit eines Rezeptor-vermittelt Apoptose in Tumorzellen auslösenden Arzneimittels |
| PL375064A1 (en) | 2002-05-20 | 2005-11-14 | Abgenix, Inc. | Treatment of renal carcinoma using antibodies against the egfr |
| DK2314629T4 (da) | 2002-07-18 | 2023-02-06 | Merus Nv | Rekombinant produktion af blandinger af antistoffer |
| US20040023390A1 (en) | 2002-08-05 | 2004-02-05 | Davidson Beverly L. | SiRNA-mediated gene silencing with viral vectors |
| CN1854313B (zh) * | 2002-09-30 | 2010-10-20 | 肿瘤疗法科学股份有限公司 | 非小细胞肺癌的诊断方法 |
| WO2004063355A2 (en) | 2003-01-10 | 2004-07-29 | Protein Design Labs, Inc. | Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer |
| JP2007528201A (ja) | 2003-03-14 | 2007-10-11 | ファルマシア・コーポレーション | 癌治療のためのｉｇｆ−ｉ受容体に対する抗体 |
| US20050214301A1 (en) | 2004-03-24 | 2005-09-29 | Cell Signaling Technology, Inc. | Antibodies specific for BCR-ABL fusion protein and uses thereof |
| PL1959955T3 (pl) | 2005-12-05 | 2011-04-29 | Pfizer Prod Inc | Sposób traktowania nieprawidłowego wzrostu komórek |
| US8383799B2 (en) | 2006-01-20 | 2013-02-26 | Cell Signaling Technology, Inc. | Translocation and mutant ROS kinase in human non-small cell lung carcinoma |
| US20100143918A1 (en) | 2007-01-19 | 2010-06-10 | Cell Signaling Technology, Inc. | Translocation and mutant ros kinase in human non-small cell lung carcinoma |
| WO2007084631A2 (en) | 2006-01-20 | 2007-07-26 | Cell Signaling Technology, Inc. | Translocation and mutant ros kinase in human non-small cell lung carcinoma |
| US20120208824A1 (en) | 2006-01-20 | 2012-08-16 | Cell Signaling Technology, Inc. | ROS Kinase in Lung Cancer |
| ES2458497T3 (es) * | 2006-04-14 | 2014-05-05 | Cell Signaling Technology, Inc. | Defectos de genes y quinasa ALK mutante en tumores sólidos humanos |
| PT2450437T (pt) | 2006-04-14 | 2017-08-25 | Cell Signaling Technology Inc | Defeitos de genes e cinase alk mutante em tumores sólidos humanos |
| CA2598893C (en) | 2006-10-11 | 2012-04-10 | Astellas Pharma Inc. | Eml4-alk fusion gene |
| SG177225A1 (en) | 2006-12-01 | 2012-01-30 | Agency Science Tech & Res | Cancer-related protein kinases |
| JP5769968B2 (ja) | 2007-10-18 | 2015-08-26 | セル・シグナリング・テクノロジー・インコーポレイテツド | ヒト非小細胞肺癌における転座および変異ｒｏｓキナーゼ |
| EP2255190A4 (en) | 2008-02-12 | 2011-05-04 | Brigham & Womens Hospital | FISH TEST FOR EML4-ALK FUSION IN LUNG CANCER |
| GB2467901A (en) | 2009-02-12 | 2010-08-18 | Norgine Bv | 3',6'-dihydroxy-5(6)-nitrospiro[2-benzofuran-3,9'-xanthene]-1-one mixt. by reacting 4-nitrophthalic acid/anhydride & benzene-1,3-diol in methanesulphonic acid |
| EP3266795A1 (en) | 2009-02-12 | 2018-01-10 | Cell Signaling Technology, Inc. | Method for detecting a fig-ros fusion polynucleotide |
| LT3009428T (lt) * | 2009-05-08 | 2018-04-10 | Astellas Pharma Inc. | Diamino heterociklinis karboksamido junginys |
| WO2011146945A2 (en) | 2010-05-21 | 2011-11-24 | Cell Signaling Technology, Inc. | Alk and ros kinase in cancer |
-
2011
- 2011-05-23 US US13/113,676 patent/US20120208824A1/en not_active Abandoned
-
2012
- 2012-05-23 DK DK12725976.0T patent/DK2715365T3/en active
- 2012-05-23 EP EP18203673.1A patent/EP3492918B1/en active Active
- 2012-05-23 CN CN201610542647.6A patent/CN106148525B/zh active Active
- 2012-05-23 JP JP2014512072A patent/JP6210977B2/ja active Active
- 2012-05-23 DK DK16196573.6T patent/DK3182128T3/en active
- 2012-05-23 PT PT16196573T patent/PT3182128T/pt unknown
- 2012-05-23 SI SI201231545T patent/SI3182128T1/sl unknown
- 2012-05-23 HU HUE16196573A patent/HUE041780T2/hu unknown
- 2012-05-23 CN CN201280036118.9A patent/CN103858011B/zh active Active
- 2012-05-23 EP EP12725976.0A patent/EP2715365B1/en active Active
- 2012-05-23 TR TR2019/02690T patent/TR201902690T4/en unknown
- 2012-05-23 KR KR1020137034188A patent/KR102123963B1/ko active Active
- 2012-05-23 CA CA3020650A patent/CA3020650C/en active Active
- 2012-05-23 CA CA2841900A patent/CA2841900C/en active Active
- 2012-05-23 ES ES16196573T patent/ES2716980T3/es active Active
- 2012-05-23 EP EP16196573.6A patent/EP3182128B1/en active Active
- 2012-05-23 WO PCT/US2012/039108 patent/WO2012162373A1/en not_active Ceased
- 2012-05-23 ES ES12725976.0T patent/ES2611281T3/es active Active
-
2017
- 2017-09-11 JP JP2017173626A patent/JP6404423B2/ja active Active
-
2018
- 2018-05-31 US US15/994,165 patent/US11099188B2/en active Active
- 2018-09-11 JP JP2018169294A patent/JP6619070B2/ja active Active
-
2021
- 2021-07-16 US US17/377,475 patent/US20210349095A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR201902690T4 (en) | ROS KINASE IN LUNG CANCER. | |
| Huo et al. | Primary pulmonary mucoepidermoid carcinoma: histopathological and moleculargenetic studies of 26 cases | |
| Shapiro et al. | An EMT–driven alternative splicing program occurs in human breast cancer and modulates cellular phenotype | |
| Koeppen et al. | Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non–small cell lung cancer: MET expression levels are predictive of patient benefit | |
| Janssens et al. | Alteration of frizzled expression in renal cell carcinoma | |
| Cáceres-Gorriti et al. | RAN nucleo-cytoplasmic transport and mitotic spindle assembly partners XPO7 and TPX2 are new prognostic biomarkers in serous epithelial ovarian cancer | |
| JP2019023645A5 (https=) | ||
| Jin et al. | Up-regulation of ECT2 is associated with poor prognosisn gastric cancer patients | |
| ES2667029T3 (es) | Marcador novedoso para la detección de cáncer de vejiga y/o afecciones inflamatorias de la vejiga | |
| ES2538362T3 (es) | Clasificación, estadificación y pronóstico del cáncer mediante el uso de osteopontina-C | |
| Chen et al. | MicroRNA‐18a modulates P53 expression by targeting IRF2 in gastric cancer patients | |
| Zhang et al. | The chromosome 11q13. 3 amplification associated lymph node metastasis is driven by miR-548k through modulating tumor microenvironment | |
| Liu et al. | Malignant pleural effusion supernatants are substitutes for metastatic pleural tumor tissues in EGFR mutation test in patients with advanced lung adenocarcinoma | |
| Zhao et al. | Hypoxia-inducible factor-1α regulates chemotactic migration of pancreatic ductal adenocarcinoma cells through directly transactivating the CX3CR1 gene | |
| Bell et al. | Head and neck adenoid cystic carcinoma: what is new in biological markers and treatment? | |
| Kneissl et al. | Association of amphiregulin with the cetuximab sensitivity of gastric cancer cell lines | |
| Cooper et al. | EGFR mutant-specific immunohistochemistry has high specificity and sensitivity for detecting targeted activating EGFR mutations in lung adenocarcinoma | |
| Zhang et al. | Clinical significance of detecting circulating tumor cells in patients with esophageal squamous cell carcinoma by EpCAM‑independent enrichment and immunostaining‑fluorescence in situ hybridization | |
| Guo et al. | Assessment of epidermal growth factor receptor mutation/copy number and K-ras mutation in esophageal cancer | |
| Viscardi et al. | Circulating biomarkers in malignant pleural mesothelioma | |
| Stoecklein et al. | Clinical application of circulating tumor cells | |
| Yang et al. | Diagnostic and prognostic value of serum interleukin‑16 in patients with gastric cancer | |
| Lacroix et al. | MET genetic abnormalities unreliable for patient selection for therapeutic intervention in oropharyngeal squamous cell carcinoma | |
| Chen et al. | CXCR4 is a prognostic marker that inhibits the invasion and migration of gastric cancer by regulating VEGF expression | |
| JPWO2017033905A1 (ja) | Ｏｃｌｎ−ａｒｈｇａｐ２６遺伝子の検出方法 |